23 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 23 of 23 clinical reviews.
A physician-reviewed deep dive into how resmetirom (Rezdiffra) affects appetite and food cravings in MASH patients, with data from MAESTRO-NASH, mechanism of action detail, and practical clinical guidance.
A physician-level review of how resmetirom (Rezdiffra) affects autoimmune conditions, including thyroid autoimmunity, immune-mediated hepatitis, and drug interactions relevant to patients with MASH and co-existing autoimmune disease.
A physician-reviewed analysis of how resmetirom (Rezdiffra) affects bone mineral density and bone turnover markers in MASH patients, with primary-literature citations and clinical guidance.
A physician-level analysis of the cancer risk signals observed with resmetirom (Rezdiffra) in MAESTRO-NASH and post-approval data, including hepatocellular carcinoma, thyroid neoplasia, and regulatory context.
A physician-level review of resmetirom's long-term cardiovascular effects, including lipid changes, MASH-CVD mechanisms, MAESTRO-NASH trial data, and what to expect beyond 52 weeks of therapy.
A detailed clinical review of how resmetirom (Rezdiffra) affects cognitive function, including MAESTRO-NASH trial data, thyroid hormone receptor biology, and what patients and clinicians need to know.
A physician-reviewed comparison of branded Rezdiffra (resmetirom) versus compounded resmetirom for MASH, covering FDA approval, pharmacology, safety, and prescribing guidance.
A GRADE-level analysis of resmetirom's clinical evidence for MASH, covering MAESTRO-NASH trial data, histological endpoints, safety, and what the evidence quality means for prescribing decisions.
A clinical deep-dive into resmetirom (Rezdiffra) hair loss, alopecia, rash, and other dermatologic adverse effects reported in MAESTRO-NASH and post-marketing surveillance, with dosing context and management guidance.
A physician-reviewed deep dive into how resmetirom (Rezdiffra) affects liver function in MASH, covering MAESTRO-NASH trial data, ALT/AST changes, histological outcomes, fibrosis regression, and safety signals.
A physician-reviewed deep dive into how resmetirom (Rezdiffra) affects mood, cognition, sleep, and psychiatric risk in MASH patients, with primary-literature citations and clinical guidance.
A physician-level review of how resmetirom (Rezdiffra) alters hepatic metabolism, mitochondrial thermogenesis, and lipid oxidation in MASH patients, with primary-literature citations throughout.
A physician-reviewed deep dive into resmetirom (Rezdiffra) dosing, the MAESTRO-NASH trial data, FDA-approved dose levels, and whether any clinical evidence supports microdosing in MASH.
A clinician-level guide to muscle preservation during resmetirom (Rezdiffra) therapy for MASH: mechanism, trial data, monitoring protocols, and practical strategies to protect lean mass.
MD-level guide to diagnosing and managing resmetirom plateau and non-response in MASH patients: dose optimization, adherence checks, combination strategies, and when to escalate care.
A comprehensive clinical review of resmetirom (Rezdiffra) use after bariatric surgery, covering pharmacokinetics, drug interactions, dosing adjustments, and evidence from MAESTRO-NASH and related trials.
A physician-level guide to the Rezdiffra (resmetirom) pre-surgery hold window, including pharmacokinetics, thyroid-axis considerations, bleeding risk, anesthetic interactions, and a practical perioperative protocol.
What happens when you stop resmetirom? This clinician-reviewed guide covers the evidence on MASH rebound, lipid changes, thyroid-axis effects, and how to taper or transition safely after discontinuing Rezdiffra.
A clinician-level review of resmetirom's renal effects in MASH patients: MAESTRO-NASH data, mechanistic rationale, safety signals, and monitoring guidance for prescribers.
A physician-reviewed deep dive into how resmetirom (Rezdiffra) affects sexual function in MASH patients, covering trial data, thyroid receptor biology, hormonal pathways, and practical clinical guidance.
A clinician-level review of how resmetirom (Rezdiffra) affects sleep architecture in MASH patients, drawing on MAESTRO-NASH trial data, thyroid-hormone receptor biology, and emerging polysomnography evidence.
MD/PharmD-level guidance on dosing resmetirom (Rezdiffra) across time zones, managing missed doses while traveling, drug interactions at altitude, and hepatic monitoring logistics for patients with MASH.
A week-by-week clinical guide to the first month on resmetirom (Rezdiffra), what labs change, which side effects peak and fade, and what MAESTRO-NASH data say about early response.